BerGenBio ASA (OSL:BGBIO)

Market Cap	53.55M
Revenue (ttm)	848.00K
Net Income (ttm)	-139.28M
Shares Out	39.09M
EPS (ttm)	-3.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	450,828
Average Volume	399,227
Open	1.348
Previous Close	1.370
Day's Range	1.336 - 1.430
52-Week Range	1.260 - 15.670
Beta	1.20
RSI	36.40
Earnings Date	Aug 20, 2025

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and immune-evasive in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and BGBIL025, a JAK2 inhibitor, which is in preclinical stage for treatment of the bone marrow disorder myelofibrosis. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Nor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Oslo Børs
• Ticker Symbol: BGBIO

Financial Performance

In 2024, BerGenBio ASA's revenue was 848,000, an increase of 139.55% compared to the previous year's 354,000. Losses were -139.28 million, -26.85% less than in 2023.